Health Catalyst (NASDAQ:HCAT) Expected to Post Quarterly Sales of $41.84 Million

Equities research analysts expect Health Catalyst (NASDAQ:HCAT) to post $41.84 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Health Catalyst’s earnings. The highest sales estimate is $42.66 million and the lowest is $40.95 million. Health Catalyst posted sales of $36.80 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.7%. The company is expected to report its next quarterly earnings results on Thursday, August 27th.

According to Zacks, analysts expect that Health Catalyst will report full-year sales of $181.83 million for the current financial year, with estimates ranging from $174.30 million to $186.99 million. For the next financial year, analysts anticipate that the company will post sales of $218.73 million, with estimates ranging from $200.80 million to $227.77 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $45.12 million for the quarter, compared to analysts’ expectations of $44.12 million. Health Catalyst had a positive return on equity of 30.42% and a negative net margin of 38.74%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year.

Several analysts have weighed in on the company. ValuEngine raised Health Catalyst from a “hold” rating to a “buy” rating in a report on Tuesday, February 18th. Canaccord Genuity assumed coverage on Health Catalyst in a report on Thursday, April 2nd. They issued a “buy” rating and a $40.00 price target on the stock. Cantor Fitzgerald lowered their price target on Health Catalyst from $47.00 to $44.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. SunTrust Banks raised their price target on Health Catalyst from $30.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Finally, Royal Bank of Canada raised their price target on Health Catalyst from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $40.33.

HCAT remained flat at $$28.36 during trading on Monday. The company had a trading volume of 422,389 shares, compared to its average volume of 824,448. The company has a 50-day simple moving average of $26.55 and a 200-day simple moving average of $31.16. Health Catalyst has a twelve month low of $17.48 and a twelve month high of $49.85. The stock has a market cap of $1.08 billion and a P/E ratio of -5.37. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.95 and a current ratio of 4.95.

In related news, COO Paul Horstmeier sold 10,750 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $28.53, for a total transaction of $306,697.50. Following the transaction, the chief operating officer now directly owns 85,750 shares in the company, valued at approximately $2,446,447.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Linda Llewelyn sold 17,944 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $28.53, for a total value of $511,942.32. Following the transaction, the insider now owns 43,321 shares in the company, valued at $1,235,948.13. The disclosure for this sale can be found here. Insiders have sold a total of 134,957 shares of company stock worth $3,623,758 over the last quarter. Corporate insiders own 22.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. New York State Common Retirement Fund grew its position in shares of Health Catalyst by 9.4% in the 4th quarter. New York State Common Retirement Fund now owns 7,000 shares of the company’s stock worth $243,000 after buying an additional 600 shares during the last quarter. Valeo Financial Advisors LLC grew its position in shares of Health Catalyst by 220.7% in the 1st quarter. Valeo Financial Advisors LLC now owns 991 shares of the company’s stock worth $25,000 after buying an additional 682 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in shares of Health Catalyst in the 4th quarter worth approximately $27,000. Baillie Gifford & Co. grew its position in shares of Health Catalyst by 34.5% in the 1st quarter. Baillie Gifford & Co. now owns 3,352 shares of the company’s stock worth $88,000 after buying an additional 860 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its position in shares of Health Catalyst by 0.5% in the 4th quarter. Lord Abbett & CO. LLC now owns 173,564 shares of the company’s stock worth $6,023,000 after buying an additional 895 shares during the last quarter. Institutional investors and hedge funds own 64.09% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services.

Featured Story: Quick Ratio

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.